Cancer Vaccines Vectorlogics is developing intradermally-administered cancer vaccines designed to selectively target dendritic cells. The VLI cancer vaccine targets dendritic cells directly through their receptors as well as indirectly through the transduction of surrounding skin cells for maximum effect. This unique and highly innovative approach represents a potentially effective treatment for a large numbers of cancers including metastatic diseases. Furthermore, it is a therapy that seeks to harness the body's own defenses to fight the uncontrolled growth and spread of cancer cells. These vaccines are biological therapies designed to stimulate the patient's immune system to destroy cancer cells that the body has become tolerant of. The first vaccine is currently in the preclinical stage of development for colorectal cancer. We believe the development of such highly specific and highly selective products as adjuvant therapy to established regimens represents significant therapeutic and commercial opportunities. Hedley SJ, Auf der Maur A, Hohn S, Escher D, Barberis A, Glasgow JN, Douglas JT, Korokhov N, Curiel DT.  (2006) An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Therapy 13: 88-94.